4.7 Article

Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patients perspective

Journal

RHEUMATOLOGY
Volume 47, Issue 2, Pages 188-193

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kem317

Keywords

rheumatoid arthritis; patient perspective; adalimumab; out-of-pocket payments

Categories

Ask authors/readers for more resources

Objectives. This study evaluated the patients perspective of burden of disease among 505 patients with severe, long-standing rheumatoid arthritis receiving adalimumab. Methods. Health-related quality-of-life and resource use data were collected during a 144-week open-label study. Results. Adalimumab maintained pain control and reduced the duration of morning stiffness. Work impairment decreased and work productivity was maintained over the duration of the study. Costs were estimated at similar to is an element of 2100 over the course of the study, and personal help and transportation costs comprised a large percentage of total costs. Conclusions. These results suggest that adalimumab could improve many aspects of a patients burden of disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available